Vesenbeckh S, Wagner S, Mauch H, Roth A, Streubel A, Rüssmann H, Bauer T T, Matthiessen W, Schönfeld N
Klinik für Pneumologie, Lungenklinik Heckeshorn, Helios Klinikum Emil von Behring, Berlin.
Institut für Mikrobiologie, Helios Klinikum Emil von Behring, Berlin.
Pneumologie. 2014 Aug;68(8):526-31. doi: 10.1055/s-0034-1377288. Epub 2014 Jul 21.
In a recent prospective study on pulmonary infections with non-tuberculous mycobacteria (NTM) led by the WATL group, disease rates in patients with M. kansasii infection were found to be 100 %. In the present study we re-evaluated the pathogenicity of M. kansasii infections in a large lung diseases treatment center in Berlin (Lungenklinik Heckeshorn).
All patients in whose respiratory specimen cultures M. kansasii was detected between January 2003 and June 2013 were included. The 2007 ATS diagnostic criteria were applied to differentiate disease from asymptomatic infection. The strains were further investigated by sequencing of the 16S-23S rDNA internal transcribed spacer (ITS) region.
We evaluated 43 consecutive cases. Complete patient data were available in 38 cases. In one patient, no culture results were obtained, in 37 patients M. kansasii was isolated and patient data could be retrieved. In 25/37 patients (68 %) clinical disease was present so that a specific treatment was initiated (underlying diseases were COPD in 8/25 (32 %), bronchiectasis in 5/25 (20 %), TB scar or scar due to prior chest surgery in 3/25 (12 %) and alcohol abuse in 4/25 (16 %)). Twelve out of 37 patients (32 %) were found to be colonized or asymptomatically infected (underlying diseases were COPD in 7/12 (58 %), bronchiectasis in 3/12 (25 %) and TB scar or scar due to prior chest surgery in 3/12 (25 %)). Sequencing results identified 30 strains as genotype I, and 2 strains as genotype II. In 22/30 cases (73 %) genotype I was considered pathogenic.
In our cohort, we could not confirm the high M. kansasii pathogenicity of 100 % found in a previous multi-center study; we therefore support the clinical and semiquantitative microbiologic diagnostic criteria also for infection with M. kansasii.
在由WATL小组牵头的一项关于非结核分枝杆菌(NTM)肺部感染的近期前瞻性研究中,堪萨斯分枝杆菌感染患者的发病率为100%。在本研究中,我们在柏林的一家大型肺病治疗中心(Heckeshorn肺病诊所)重新评估了堪萨斯分枝杆菌感染的致病性。
纳入2003年1月至2013年6月期间呼吸道标本培养物中检测到堪萨斯分枝杆菌的所有患者。采用2007年美国胸科学会(ATS)诊断标准区分疾病与无症状感染。通过对16S-23S核糖体DNA内转录间隔区(ITS)进行测序对菌株作进一步研究。
我们评估了43例连续病例。38例患者有完整的患者数据。1例患者未获得培养结果,37例患者分离出堪萨斯分枝杆菌并可检索到患者数据。37例患者中有25例(68%)存在临床疾病,因此开始了特异性治疗(基础疾病为慢性阻塞性肺疾病(COPD)的有8/25例(32%),支气管扩张的有5/25例(20%),结核瘢痕或既往胸部手术瘢痕的有3/25例(12%),酗酒的有4/25例(16%))。37例患者中有12例(32%)被发现为定植或无症状感染(基础疾病为COPD的有7/12例(58%),支气管扩张的有3/12例(25%),结核瘢痕或既往胸部手术瘢痕的有3/12例(25%))。测序结果确定30株为I型基因型,2株为II型基因型。22/30例(73%)的I型基因型被认为具有致病性。
在我们的队列中,我们无法证实先前多中心研究中发现的堪萨斯分枝杆菌100%的高致病性;因此,我们也支持针对堪萨斯分枝杆菌感染的临床和半定量微生物学诊断标准。